Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating the Efficacy and Safety of Yoni.Fit in Women With Stress Urinary Incontinence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03978741
Recruitment Status : Recruiting
First Posted : June 7, 2019
Last Update Posted : August 18, 2020
Sponsor:
Information provided by (Responsible Party):
Watkins Conti Products. Inc.

Brief Summary:
Study to evaluate the safety and effectiveness of Yoni.Fit for the temporary management of stress urinary incontinence (SUI) in women.

Condition or disease Intervention/treatment Phase
Urinary Incontinence Device: Yōni.Fit Test Device Device: Yōni.Fit Comparator Device Not Applicable

Detailed Description:
Randomized, comparator-controlled, single blinded, multicenter study to demonstrate the effectiveness, user acceptance, safety and tolerability of Yoni.Fit in the temporary management of stress urinary incontinence (SUI) in women.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Randomized, Comparator-controlled, Single Blinded, Multi-center Study Evaluating the Efficacy and Safety of Yoni.Fit in Women With Stress Urinary Incontinence
Actual Study Start Date : January 3, 2020
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Test Device
Yōni.Fit Test Device
Device: Yōni.Fit Test Device
The Yōni.Fit Test Device is a silicone pressary.

Active Comparator: Comparator Device
Yōni.Fit Comparator Device
Device: Yōni.Fit Comparator Device
The Yōni.Fit Comparator Device is a silicone pressary.




Primary Outcome Measures :
  1. Responder rate at Day 21 [ Time Frame: 21 Days ]
    Responder rate at Day 21, where responder is defined as a subject who has at least 50% reduction in mean 12-hour pad weight test through assessment period of treatment phase (the last 7 days of 14-day device usage period), when compared to the mean pad weight test during the 7-day baseline phase


Secondary Outcome Measures :
  1. Percent Change in mean pad weight [ Time Frame: 7 Days, 14 Days ]
    Percent change in mean pad weight during assessment period of treatment phase (the last 7 days of 14-day device usage period), from the mean pad weight during the 7-day baseline phase

  2. Percent change in the frequency of SUI events per the patient diary [ Time Frame: 7 Days, 14 Days ]
    Percent change in the frequency of SUI events per the patient diary, defined as average number of incontinence episodes per 12 hours during assessment period of treatment phase (the last 7 days of 14-day device usage period), from the average of baseline phase

  3. Responder rate for frequency of SUI events per the patient diary at Day 21, [ Time Frame: 21 Days ]
    Where responder is defined as a subject who has at least 50% reduction in the number of incontinence episodes per day during the last 7 days of

  4. Percent change in Incontinence Impact Questionnaire (IIQ-7) score [ Time Frame: 21 Days ]
    7 questions about how urinary incontinence has affected a subjects life. Questions cover physical activity, travel, social relationships and emotional health. The questionnaire asks whether the subjects life has been greatly affected, moderately, slightly or not affected at all.

  5. Percent change in Patient Global Impression of Change (PGIC) score [ Time Frame: 21 Days ]
    It gives a patient reported assessment of change after intervention. The higher the score, the greater the severity (1 being "very much improved"; 7 "very much worse").

  6. Percent change in Incontinence-Quality of Life (I-QOL) Assessment Questionnaire [ Time Frame: 21 Days ]
    The I -QOL consists of 22 items, all of which use a five - point ordinal response scale in which 1 = extremely, 2 = quite a bit, 3 = moderately, 4 = a little, and 5 = not at all. The 22 items can be further grouped into 3 sub-scales: Avoidance and Limiting Behaviour (8 ite ms), Psychosocial Impacts (9 items), and Social Embarrassment (5 items). The total I -QOL and 3 sub scale scores are calculated by summing the unweighted item score and transforming them to a 100 point scale where 0 = mo st severe, and 100 = no problem .

  7. Ease of use per the USE Questionnaire: Usefulness, Satisfaction, and Ease of Use [ Time Frame: 21 Days ]
    The USE questionnaire is meant to be used to assess the Subjective reactions to the usability of the Yōni.Fit ® device. The "Usefulness" section of the questionnaire consists of 19 questions regarding usability of the device scaled from 1- "strongly disagree" to 7- "strongly agree."

  8. Ease of use per the USE Questionnaire: Satisfaction [ Time Frame: 21 Days ]
    The USE questionnaire is meant to be used to assess the Subjective reactions to the usability of the Yōni.Fit ® device. The "Usefulness" section of the questionnaire consists of 7 questions regarding Satisfaction with the device scaled from 1-"strongly disagree" to 7-"Strongly Agree."

  9. Ease of use per the USE Questionnaire:Ease of Use [ Time Frame: 21 Days ]
    The USE questionnaire is meant to be used to assess the Subjective reactions to the usability of the Yōni.Fit ® device. The "Usefulness" section of the questionnaire consists of 11 questions regarding Ease of Use with the device scaled from 1-"strongly disagree" to 7-"Strongly Agree."



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participants must be female,
  2. Must be 18 years of age or older at the time of signing the informed consent
  3. With BMI < 35
  4. Must meet the following 2 criteria for diagnosis of stress urinary incontinence (SUI) :

    1. SUI clinical diagnosis via the cough supine test, AND
    2. ≥ 3 month history of experiencing Stress Urinary Incontinence (SUI) symptoms per the patient
  5. Women of childbearing potential not intending to become pregnant for the duration of study participation. Subject must agree for the duration of the study to use one of the following forms of contraception

    1. Systemic hormonal treatment including oral pills, patches and injections OR
    2. "Single-barrier" contraception (condom, diaphragm and spermicide are each considered a barrier) OR
    3. Essure® procedure done at least three month prior to screening
  6. Willing to comply with study requirements, including capable of performing the activities required for the pad weight test and return for follow-up visits.
  7. Must be able to speak, understand and read English and sign study specific Informed Consent Form

Exclusion Criteria:

  1. Women having predominantly urge or mixed incontinence as defined by:

    1. QUID Urge score >6, OR
    2. MESA percentage Urge Score > MESA percentage Stress Score Note: the questionnaires above will be self-administered and results interpreted by the subjects as per instructions in the questionnaires.
  2. Current pregnancy, lactation or planning for pregnancy in the next 6 months
  3. Women at postpartum for 3 months or less prior to screening
  4. Women currently have an intrauterine device (IUD) as a contraception method placement less than 6 months or have an IUD over 6 month but may replace it next 14 weeks
  5. Women currently use, have used an intra-vaginal device as contraception method for the past 6 months
  6. Women currently using a pessary or treated previously with any device for UI
  7. Women who have been treated with pharmacologic medications for UI within the past 4 months prior to screening, including any antidiuretic or diuretic medications (both over the counter and prescription medications)
  8. Women who have been previously treated with any surgical or electrical interventions for UI
  9. Women who have been previously treated with pelvic floor muscle training (PFMT) for UI within the past 4 months prior to screening
  10. Women who have difficulty inserting or wearing an intra-vaginal device, including a tampon
  11. Women who participated in a clinical trial within the 12 months prior to screening
  12. Any of the following known conditions deemed prohibitory:

    1. Abnormal kidney function, including kidney stone
    2. Abnormal post void residual (e.g. greater than 150cc) or self-reported difficulty emptying bladder
    3. Allergy to silicon products and materials
    4. Acute febrile illness of any cause in the 14 days prior to screening
    5. Bladder stones or Bladder tumors
    6. Chronic pelvic pain within the past 4 months prior to screening
    7. Coagulation abnormalities
    8. Experience pain or burning sensation during sexual intercourse or urination
    9. Infections of the vagina, bladder and/or urethra within previous 3 months such as urinary tract infection (UTI)
    10. Interstitial cystitis
    11. Neurological disorders such as multiple sclerosis, spina bifida, Parkinson's disease which may interfere with nerve function of the bladder.
    12. Toxic shock syndrome (TSS) history or symptoms consistent with TSS
    13. Uncontrolled diabetes
    14. Undiagnosed vaginal bleeding or hematuria
    15. Vaginal discharge with a strong odor and irritation within previous 3 months
    16. Vaginal soreness or pain or fibromyalgia or paravaginal defect
  13. Any other medical reason that the Investigator determines that the subject should not participate in the study
  14. Known history of previous pelvic organ prolapse greater than the POP-Q Stage 2 as defined by the international continence society (ICS).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03978741


Contacts
Layout table for location contacts
Contact: Dominique Malacarne Pape, MD 646-825-6300 Dominique.Malacarne@nyulangone.org
Contact: Christine Escobar, MD 646-825-6300 Christina.Escobar@nyulangone.org

Locations
Layout table for location information
United States, New York
NYU Langone Health Recruiting
New York, New York, United States, 10016
Contact: Dominique Malacarne Pape    646-825-6300    Dominique.Malacarne@nyulangone.org   
Principal Investigator: Dominique Malacarne Pape, MD         
Sponsors and Collaborators
Watkins Conti Products. Inc.
Investigators
Layout table for investigator information
Principal Investigator: Dominique Malacarne Pape, MD New York Langone Medical Center
Layout table for additonal information
Responsible Party: Watkins Conti Products. Inc.
ClinicalTrials.gov Identifier: NCT03978741    
Other Study ID Numbers: 18-02041
First Posted: June 7, 2019    Key Record Dates
Last Update Posted: August 18, 2020
Last Verified: August 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Incontinence
Enuresis
Urinary Incontinence, Stress
Urination Disorders
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Behavioral Symptoms
Elimination Disorders
Mental Disorders